What the Zepbound® documents say about urine
Zepbound®’s US label lists side effects that occurred in at least 2% of people on Zepbound® and more often than with placebo in SURMOUNT-1 and SURMOUNT-2; urinary frequency, urgency and night-time urination are not among them. [1] The Canadian monograph uses a 1% cut-off for the same trials and does not list them either, and neither does the EU product information for tirzepatide, which is sold in Europe as Mounjaro®. [3][4]
Urine does appear in two places. The pharmacology section notes that tirzepatide is broken down and its metabolites leave the body in urine and stool; the intact drug is not found in either. [1] And the safety section warns about kidney injury from fluid loss, described below.
| Source | Frequent urination | Related finding |
|---|---|---|
| US label, Table 1, SURMOUNT-1 and -2 [1] | Not listed | Acute kidney injury 0.5% vs 0.2% placebo (§6.1) |
| US label §5.3 [1] | Not mentioned | Kidney injury reports mostly after nausea, vomiting or diarrhea causing dehydration |
| Canadian monograph [3] | Not listed (≥1% table) | Acute kidney injury 0.5% vs 0.2% in SURMOUNT-1, -2 and -3; dark, strong-smelling urine as a dehydration sign |
| EU, tirzepatide sold as Mounjaro® [4] | Not listed | — |
| Meta-analysis of 15 trials [5] | Not studied | No increase in urinary infection, kidney stones or kidney injury |
Research on tirzepatide and the urinary tract
A 2025 systematic review pooled 15 randomised trials with 14,471 participants who received tirzepatide for diabetes or obesity. Tirzepatide reduced protein leakage into urine at 10 and 15 mg, did not change kidney filtration compared with insulin, and did not increase the risk of urinary tract infection, kidney stones, acute kidney injury or kidney cancer compared with placebo, insulin or GLP-1 medicines. [5] The trials lasted 26 to 72 weeks, and the authors call for longer studies.
For bladder control, the evidence is indirect. A 2026 urology review notes possible benefit for stress incontinence and overactive bladder through weight loss, but also an almost complete lack of data in women. [6] A 2026 systematic review of obesity and urological disease found that incontinence and overactive bladder improved or resolved in 50–70% of women after bariatric surgery; for GLP-1 medicines, it reported kidney benefits, not bladder outcomes. [7] We found no study measuring urinary frequency as an outcome of Zepbound® treatment.
Likely reasons for more trips to the bathroom
Without a label signal, the explanations come from general medicine. Three are especially relevant to people using Zepbound®.
- Drinking more. The Medication Guide asks people on Zepbound® to drink fluids to reduce the chance of dehydration. [2] MedlinePlus lists drinking large amounts of water, and also caffeine and alcohol, among causes of passing more urine. [10] If your fluid intake went up when you started, more urine is the expected result.
- Sleep apnea. The National Heart, Lung, and Blood Institute lists waking often during the night to urinate among sleep apnea symptoms. [8] Zepbound® is approved for moderate to severe sleep apnea in adults with obesity, [1] so night-time trips may reflect breathing during sleep rather than the injection.
- Blood sugar. Poorly controlled diabetes is a cause of both frequent and excessive urination. [9][10] Tirzepatide lowers blood glucose, [1] so this is a reason to check glucose if you have diabetes and urination rises, not a predicted effect of Zepbound®.
Other causes of frequent urination
MedlinePlus lists urinary tract infection, an enlarged prostate in middle-aged and older men, inflammation of the urethra or vagina, nerve problems and caffeine as common causes of frequent or urgent urination. Less common ones include alcohol, anxiety, pregnancy, overactive bladder, water pills (diuretics), stroke and, rarely, bladder or pelvic tumours. [9] Signs pointing to infection include burning when passing urine, cloudy or bloody urine, and fever or pain in the back or side. [9][11]
Medicines are worth reviewing. Diuretics are often used for high blood pressure, which four in ten SURMOUNT participants had at the start; [1] if a diuretic was started or changed around the same time as Zepbound®, mention it. [10]
What general guidance suggests
Zepbound®’s Medication Guide has no advice about urination. Its fluid message points the other way: drink enough to avoid dehydration, and contact your prescriber promptly if nausea, vomiting or diarrhea does not settle. [2] Cutting fluids to reduce bathroom trips could work against that, so discuss it first.
MedlinePlus suggests keeping a voiding diary, a simple record of when you urinate, how much, and what you drink, to bring to your appointment. [9][10] For night-time urination it suggests not drinking a lot just before bed and cutting down on caffeinated and alcoholic drinks. [9] If sleep apnea is part of the picture, keep using any breathing device as prescribed; Zepbound® does not replace it. [3]
Zepbound® and Mounjaro® are registered trademarks of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Eli Lilly and Company.
When to get help
The signs and contact information below come from this article’s sourced guidance.
Emergency
- Very little or no urine, very dark urine, confusion, a racing heart or fainting
Contact: Emergency care (severe dehydration)
MedlinePlus [12]
Today
- Frequent urination with fever, back or side pain, vomiting or shaking chills
Contact: Contact your provider right away
MedlinePlus [9]
- Increased thirst or appetite, tiredness or sudden weight loss with frequent urination
Contact: Contact your provider right away (check blood sugar)
MedlinePlus [9]
- Dark, strong-smelling urine with extreme thirst or dizziness, especially after vomiting or diarrhea
Contact: Your prescriber, the same day